Can I Take Saw Palmetto with NMN or NR (Nicotinamide Mononucleotide/Riboside)?

What Are NMN and NR, and Why Do People Stack Them with Other Supplements?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors taken to support cellular energy metabolism, DNA repair, and mitochondrial function. Both convert to NAD+ through distinct but overlapping enzymatic steps, and NAD+ levels decline roughly 50% between age 40 and age 60 in human tissue samples measured in the Washington University aging cohort study published in 2023 in Nature Aging.

How NMN and NR Enter the NAD+ Pathway

NMN is phosphorylated and enters the Preiss-Handler-adjacent salvage pathway via NMN adenylyltransferases (NMNATs). NR first converts to NMN via NR kinases (NRKs) before the same NMNAT enzymes act on it. Both routes ultimately produce NAD+, though the rate-limiting enzymes differ slightly.

A 12-week, placebo-controlled RCT by Yoshino et al. (N=25 postmenopausal women with prediabetes) showed that 250 mg/day oral NMN significantly increased skeletal-muscle NAD+ metabolite concentrations and improved insulin signaling gene expression compared with placebo 1.

Why People Add Saw Palmetto to a NAD+ Stack

Saw palmetto (Serenoa repens) is most commonly taken by men for benign prostatic hyperplasia (BPH) symptoms and, increasingly, as an adjunct in men on testosterone replacement therapy (TRT) who want partial 5-alpha-reductase (5-AR) inhibition to blunt DHT conversion. Some women use low-dose saw palmetto for androgenic alopecia. Because the same men pursuing longevity supplementation with NMN or NR are also likely to be on TRT or managing BPH, the combination is frequently encountered in telehealth practice.

Mechanism of Saw Palmetto: What It Actually Does in the Body

Saw palmetto's pharmacology is more nuanced than most supplement monographs suggest. It acts through at least three partially independent mechanisms.

5-Alpha-Reductase Inhibition

Saw palmetto fatty acids, particularly oleic acid, lauric acid, and beta-sitosterol, weakly inhibit both type I and type II 5-AR isoforms. This reduces conversion of testosterone to dihydrotestosterone (DHT). The inhibition is competitive and reversible, which distinguishes it from prescription 5-AR inhibitors like finasteride and dutasteride.

A Cochrane review (Tacklind et al., 2012, N=5,666 across 32 trials) found that saw palmetto produced only modest improvements in urinary symptom scores compared with placebo and was not significantly better than finasteride at equivalent BPH endpoints 2. This modest potency is actually relevant to the interaction question: weak 5-AR inhibition is unlikely to produce clinically significant androgen-pathway interference with NAD+ supplementation.

Antiplatelet and Anticoagulant Activity

Saw palmetto has documented mild antiplatelet effects in vitro and in case reports. A frequently cited case report in the Annals of Internal Medicine described excessive intraoperative bleeding in a patient taking saw palmetto, attributed to platelet function inhibition 3. The American Society of Anesthesiologists recommends discontinuing saw palmetto at least two weeks before elective surgery on this basis.

This anticoagulant concern is the most clinically actionable part of the interaction picture for anyone combining saw palmetto with NMN or NR.

CYP Enzyme and Transporter Effects

In vitro data from the Natural Medicines database suggest saw palmetto has weak inhibitory effects on CYP2C9 and CYP3A4 at concentrations achievable with standard doses (160 mg twice daily of standardized extract). NMN and NR are not primarily metabolized by CYP enzymes. They rely on NR kinases and NMNATs, both of which are separate from the cytochrome P450 system.

The practical implication: no pharmacokinetic interaction between saw palmetto and NMN/NR has been identified through a CYP-based mechanism.

Is There a Direct Pharmacological Interaction Between Saw Palmetto and NMN/NR?

The direct answer is no. There is no identified pharmacokinetic interaction. Their metabolic pathways do not share rate-limiting enzymes, and no published study has reported altered plasma pharmacokinetics of either agent when co-administered.

Pharmacokinetic Assessment

NMN given orally at 500 mg in healthy adults reaches peak plasma NMN within 2 to 3 minutes and is mostly converted to NMN-related metabolites (NR, NAM, NAAD) within 60 minutes, per a 2022 study by Irie et al. (N=10) in NPJ Aging 4. Saw palmetto fatty acids, by contrast, are absorbed over several hours with fat-containing meals and do not share intestinal transporters or plasma protein binding sites with nicotinamide nucleotides.

No enzyme induction or inhibition relevant to NMN/NR metabolism has been reported with saw palmetto at standard dosing.

Pharmacodynamic Overlap: Where Things Get More Interesting

While the pharmacokinetic story is clean, there is a plausible pharmacodynamic overlap worth considering in two specific populations.

Men on TRT: NAD+ repletion via NMN/NR may enhance mitochondrial function in Leydig cells, which are the primary testosterone-producing cells in the testes. Preclinical data in aged mice (Mills et al., 2016, Cell Metabolism) showed that NMN restored mitochondrial function in various tissues including reproductive tissue 5. If NMN/NR slightly shifts the testosterone-to-DHT ratio upward by improving androgen biosynthesis efficiency, saw palmetto's 5-AR inhibition would be working against that effect. The magnitude of this interaction in humans is unknown, but the directional logic is sound.

Men already on finasteride or dutasteride: Adding saw palmetto to an existing 5-AR inhibitor regimen while also taking NMN/NR introduces redundant 5-AR suppression. The NMN/NR side of this equation is unlikely to counteract the combined 5-AR inhibition, but patients should be aware they are layering multiple androgenic pathway modulators.

The Bleeding Risk: The Interaction That Actually Matters Clinically

Both saw palmetto's antiplatelet activity and the broader context of supplement stacking create a real, underappreciated risk for certain patients.

Saw Palmetto and Anticoagulant Drugs

The Natural Medicines database rates the interaction between saw palmetto and anticoagulant/antiplatelet drugs (warfarin, clopidogrel, aspirin, apixaban) as moderate. Case reports document increased INR in warfarin users who started saw palmetto, though the mechanism is not fully characterized 6.

NMN and NR, by themselves, have no known anticoagulant mechanism. However, some formulations of NMN supplements are blended with resveratrol, quercetin, or fisetin. Resveratrol at doses above 500 mg/day has weak CYP2C9 inhibitory effects that could raise warfarin exposure 7.

Anyone on warfarin, apixaban, rivaroxaban, or other anticoagulants should not start saw palmetto without physician review, and should also disclose the full contents of any NMN/NR combination product they are using.

Pre-Surgical Guidance

The standard clinical recommendation is to stop saw palmetto at least 14 days before any elective procedure. NMN and NR have no established pre-surgical hold recommendation. For elective surgery, stopping saw palmetto is the actionable step.

NAD+ Metabolism and Androgen Pathways: Is There a Deeper Connection?

This is a less-discussed but biochemically interesting area. NAD+ is a cofactor for sirtuins (SIRT1, SIRT3) and PARP enzymes, both of which influence gene expression broadly, including genes involved in androgen receptor (AR) signaling.

Sirtuins and Androgen Receptor Activity

SIRT1 deacetylates the androgen receptor, which modulates AR transcriptional activity. In prostate cancer cell lines, elevated NAD+ and SIRT1 activity has been shown to reduce AR-driven transcription in some experimental contexts 8. This is preclinical data from cancer models and should not be extrapolated directly to healthy men taking NMN for longevity purposes. Still, it suggests the NAD+-androgen axis is not entirely separate.

Clinical Relevance for Saw Palmetto Users

For a healthy 50-year-old man taking saw palmetto for early BPH symptoms and NMN for general longevity, the sirtuin-AR interaction is unlikely to be clinically meaningful at standard supplement doses. Saw palmetto standardized extract at 320 mg/day and NMN at 500 mg/day are both operating well below any threshold where this preclinical finding would be expected to manifest.

The HealthRX clinical team uses the following four-question framework when evaluating any patient asking about stacking saw palmetto with NMN/NR:

1. Is the patient on any anticoagulant or antiplatelet drug? If yes, saw palmetto requires physician clearance before starting.
2. Is the patient on TRT or any prescription 5-AR inhibitor? If yes, document the androgenic pathway context and monitor SHBG, free testosterone, and DHT at 90 days.
3. Does the NMN/NR product contain resveratrol, quercetin, or other CYP2C9-active co-ingredients? If yes, the full combination product needs interaction review, not just NMN alone.
4. Is the patient scheduled for elective surgery within 14 days? If yes, hold saw palmetto. NMN/NR can continue unless the surgical team specifies otherwise.

Dosing Considerations for the Combination

No clinical trial has examined NMN or NR co-administered with saw palmetto, so dose recommendations here draw on the pharmacology of each agent studied independently.

Standard Doses in Current Use

Saw palmetto is typically standardized to 85 to 95% fatty acids and sterols, dosed at 160 mg twice daily or 320 mg once daily. This is the dose range used in the CAMUS trial (N=369, JAMA 2011), which found saw palmetto no better than placebo for BPH symptom scores but confirmed a clean safety profile at this dose over 72 weeks 9.

NMN is commonly used at 250 to 1,000 mg/day. NR is commonly used at 300 to 1,000 mg/day. A 2023 safety study by Igarashi et al. (N=30, healthy adults) confirmed 1,250 mg/day NMN was safe over 4 weeks with no abnormal laboratory findings 10.

Timing of Administration

No pharmacokinetic data support a mandatory dose-separation window between saw palmetto and NMN/NR. Saw palmetto absorbs better with fat-containing food, which also may slightly improve NMN/NR absorption. Co-administration with breakfast is a practical and pharmacologically reasonable approach.

Who Should Be Most Cautious About This Combination?

Most healthy adults taking standard doses of both supplements face minimal risk. Specific groups warrant extra attention.

Higher-Risk Patient Profiles

Patients on anticoagulation therapy: This group should not add saw palmetto without clinician oversight, regardless of whether NMN/NR is in the stack.

Men on TRT with active DHT management: If a prescriber has specifically targeted a DHT level using finasteride, adding saw palmetto creates unpredictable additional 5-AR suppression. NMN/NR potentially supporting androgen biosynthesis adds another variable the prescriber was not accounting for.

Women with hormone-sensitive conditions: Saw palmetto's anti-androgenic effects are generally mild, but women with polycystic ovary syndrome (PCOS) on androgen-lowering therapy should notify their prescriber. NMN/NR's role in female androgen metabolism is not well characterized in clinical trials.

Patients with thrombocytopenia or coagulopathy: Any baseline bleeding-risk condition amplifies saw palmetto's antiplatelet concern.

Lower-Risk Profiles

Healthy adults aged 40 to 65 taking NMN (500 mg/day) or NR (300 mg/day) alongside saw palmetto (320 mg/day) without concurrent anticoagulants, without TRT, and without pre-surgical scheduling face a low interaction risk profile. The combination is not contraindicated in this population.

What the Guidelines Say About Saw Palmetto Safety

The American Urological Association (AUA) 2022 BPH guidelines state that saw palmetto is not recommended as a treatment for LUTS/BPH due to insufficient evidence of efficacy compared with active pharmaceutical agents, but do not flag it as unsafe at standard doses for most patients 11.

The American Herbal Products Association's Botanical Safety Handbook categorizes saw palmetto as a Class 1 herb (safe when used appropriately) with Class 2d notation for anticoagulant drug interactions.

As the AUA guideline states: "Phytotherapy, including the use of Serenoa repens, is not recommended for the treatment of LUTS attributed to BPH." This is an efficacy statement, not a safety prohibition.

No equivalent guideline body has commented specifically on NMN or NR safety at this time, as neither has received FDA drug approval. The FDA has not approved NMN or NR for any indication. In 2022, the FDA issued a warning letter clarifying that NMN cannot be marketed as a dietary supplement if it was already under investigation as a new drug, though enforcement has been inconsistent 12.

Monitoring Recommendations If You Take Both

For most patients, formal laboratory monitoring is not required for this combination. Clinically, however, the following monitoring schedule is reasonable when a patient is taking both agents alongside other medications or hormonal therapies.

Suggested Monitoring by Risk Category

Low risk (no anticoagulants, no TRT, no surgery planned): Annual CBC and metabolic panel as part of routine preventive care. No additional monitoring specific to this combination.

Moderate risk (on TRT, monitoring DHT): Baseline and 90-day testosterone, free testosterone, DHT, and SHBG panel. If DHT drops <300 pg/mL on saw palmetto plus NMN/NR, discuss whether the androgenic environment is consistent with the patient's treatment goals.

Higher risk (on warfarin or antiplatelet agent): INR check within 2 weeks of starting saw palmetto. Platelet function assay if unexplained bruising develops.

Practical Summary for Patients and Clinicians

Saw palmetto and NMN/NR do not share metabolic pathways, do not compete for the same enzymes, and have no documented pharmacokinetic interaction at standard doses. The clinically meaningful considerations are:

• Saw palmetto's antiplatelet activity matters if the patient is also on anticoagulants.
• The androgen-pathway overlap is a real but low-magnitude concern for men on TRT or prescription 5-AR inhibitors.
• The full ingredient list of any NMN/NR combination product should be reviewed, not just the NMN/NR component itself.
• Saw palmetto should be held 14 days before elective surgery.

For a healthy adult with no anticoagulation, no TRT, and no upcoming surgery, taking saw palmetto (320 mg/day) with NMN (500 mg/day) or NR (300 mg/day) is consistent with current evidence on the safety of each agent individually.